Indicator -This analysis focused on estimating viremic HCV infections, which are indicated by the presence of HCV RNA. The analysis used anti-HCV prevalence, serological evidence of past or present infection and the viremic rate in a Markov model to estimate the end-of-year viremic prevalence in 2015.
Markov model -The Markov model described here is an open-source model that is provided to academic and government researchers upon request. Modellers and epidemiologists in France, Greece, Australia, Egypt, Spain and Portugal have independently reviewed the model and provided feedback for modifications and updates. In addition, experts in 59 countries continue to provide requests for updates to the model to enhance its functionality and algorithms. Since its inception in 2012 (31) , the model has undergone over 80 revisions and updates.
The Markov (disease progression) model was constructed in Microsoft Excel® (Microsoft Corp., Redmond, WA) to quantify the annual size of the HCV-infected population by stage of liver disease over 1950-2050. The size and impact of the HCV-infected population prior to 1950 was considered negligible for the purposes of this analysis. Microsoft Excel was selected as a platform due to its transparency, availability and minimal need for operator training. The disease progression was modelled using the flow shown in the figure below and the calculations shown in Equation 1.
The model started with the annual number of acute infections that progressed to chronic (viremic) HCV infection after accounting for spontaneous clearance of the virus. The methodology to calculate incidence is described below. The progression of these new cases was followed, along with all chronic infections from prior years. Unless otherwise specified, the scope of the model was limited to viremic, HCV ribonucleic acid (RNA)-positive cases. Non-viremic cases (those who were exposed to the virus but either spontaneously cleared it or were treated and cured) were not considered.
The number of new (incident) cases at each stage of disease was calculated annually by multiplying the annual progression rate by the prevalent population (by age and sex) in the previous stage, less cures and deaths. Thus, the annual number of new F2 cases was calculated by multiplying the prevalent population in F1 (by age and sex) less cures and deaths in the prevalent population in F1 by the F1-F2 progression rate.
The prevalent population at each stage of disease was tracked by one-year age group and was aged (progressed to the next age group) annually. The progression rates were back-calculated using five-year age groups (as described below). In this model, the progression rate was assumed to be constant over the five-year age group. Thus, for ages 5-9, the F1-F2 progression rate was assumed to be constant. 
where:
, , is the annual background mortality rate at time , for sex , at age , , , is the annual liver-related mortality rate for stage , at time , for sex , at age New cases , , , is the number of cases incident or progressing to stage , at time , for sex , at age .
Progression rates -The progression rates by age, sex and fibrosis score were back-calculated. Data from the UK were used for the percentage increase in progression rate by age and sex (32) . However, this study only reported progression from chronic HCV to moderate chronic HCV and from moderate chronic HCV to cirrhosis. These reported rates were modified using a meta-analysis of published work to calculate progression rates for F0, F1, F2, F3 and F4 (33) . Finally, the modified progression rates were adjusted to fit historical HCC incidence by age and sex in the U.S. (34) having adjusted for the portion of all HCC cases attributed to HCV infection (35) . The progression rates to end-stage liver disease and liver-related death were based on previously published rates. Insufficient data were available to develop predictable rates by age and sex. Thus, the same rate was applied for all ages and both sexes (36) (37) (38) Incidence -The following methodologies were used to estimate incidence in each country.
Historical Incidence
Countries with two prevalence studies -When two prevalence studies with age and sex distribution were available, they were used to calculate the average number of incident cases between the two time points. Countries that have reported HCV prevalence at two points in time include the United States, France and Egypt. The prevalence by age in the older studies was fed into a model that aged the population while taking into consideration background deaths, liver-related deaths and the number of individuals treated and cured. The average annual incidence was calculated from the difference in prevalence between the older study (after the above adjustments) and the new study.
Back-calculation of incidence -When reliable prevalence estimates were available at only one point in time, a back-calculation methodology was used to estimate the incidence by year. In this case, the prevalence of HCV in 1950 (among those who are still alive at the time of known prevalence) was assumed to be zero, and the same methodology as above was used to estimate the average annual number of new infections per year between 1950 and the year of known prevalence. In countries with a long life expectancy and known sources of infection prior to 1950 (e.g., Japan), adjustments were made to the prevalent population in 1950 to account for cases that are still alive today. The analysis was refined by developing a relative incidence curve with the 1950 relative incidence set to 1. The relative incidence was mapped based on the known risk factors and the start of blood screening in the country. In approved models, these relative incidence curves were discussed at length with the expert panel in order to best estimate the historical "shape" of the epidemic relative to 1950. For example, in many counties the incidence of HCV was estimated to increase (relative to 1950) beginning around the 1960s or 1970s, and then decrease in the 1990s as HCV screening tests became more prevalent in blood banks and transfusion centres. Incidence data on acute infections were also used to inform the incidence trends in the model.
The model was used to find a value for the annual relative incidence that resulted in the known prevalence after adjusting for mortality and cures. In this calibration step, the number of new infections shown in Equation 2 was calculated to fit the known prevalence in a given year y.
Equation 2. Total HCV infections in year y
Total HCV infections Year = � �New infections t -Spontaneous clearances t -Deaths t -Cures t � y t=1950
The annual incident cases were distributed by age and gender, and the modelled distribution was compared to the reported distribution. An iterative process of modifying the relative incidence curve and allocation by age was used to match the two curves and estimate the annual number of new infections by year.
Current & Future Incidence
The current incidence (after the known prevalence) was calculated by using the last year's incidence and/or asking the experts from each country if they expected the future prevalence to decline, stay the same or increase. The rate of growth or decline was also collected. This was then used in the model to calculate the minimum annual incidence per year needed to achieve the desired growth rate. In the absence of better information, it was assumed that the number of new infections per year would stay constant in the future.
Validation of the model -
The modelled outputs for 1990-2013 were validated against empirical data. Incident liver cancer data were obtained from the National Institute for Cancer Epidemiology and Registration and adjusted for hepatocellular carcinoma (HCC) based on histology data from the Geneva Tumour Registry. Histological data were available for 52% of tumours, of which approximately 91% were HCC. In the absence of better information, we assumed that the remaining 48% of tumours had a similar histological profile and included a range to capture the significant associated uncertainty: 91% (0-100%) HCC. The percentage of HCC attributable to HCV infection was estimated to be 44.5% (range 43.3-53.3%) (10) . 
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